Get to know our clinical trials
Phase I clinical trial in humans of MEN2501 as monotherapy in participants with platinum-resistant ovarian cancer
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF MEN2501 AS A MONOTHERAPY IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- FIRST PHASE I CLINICAL TRIAL IN HUMANS OF MEN2501, A KIF18A INHIBITOR, AS MONOTHERAPY IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER
- Code EudraCT: 2025-524168-39
- Protocol number: MEN2501-01
- Promoter: Stemline Therapeutics
- Molecule/Drug: MEN2501
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.